# JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

Source: https://onco.cc/trials/nct06595186/  
OnCo record `nct06595186` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Temozolomide in glioma & glioblastoma, run by JenKem Technology Co., Ltd., now recruiting.

## Summary

JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) is a phase 2 interventional study registered as NCT06595186 by JenKem Technology Co., Ltd., with 25 participants planned, started 2022-10-31 and due to reach its primary completion in 2026-08-16. Interventions recorded: JK-1201I and Temozolomide (TMZ).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06595186
- Phase: 2
- Setting: A Multicenter, Single Arm, Open-label, Dose-escalation Phase 2 Study of JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) After Surgery and Concomitant Radio-chemotherapy
- Sponsor: JenKem Technology Co., Ltd.
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT06595186: https://clinicaltrials.gov/study/NCT06595186

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)

---
JSON: https://onco.cc/api/v1/entities/nct06595186.json